No profile data available.
FibroGen, Inc. (FGEN) is a healthcare company in the drug manufacturing contractors industry, based in San Francisco, United States, with about 225 full-time employees.
It reported revenue of $29.62 million for fiscal year 2024, down 36.7% from fiscal year 2023, and net income of -$47.58 million. In Q2 2025 (the quarter ended June 30, 2025) revenue was $1.35 million, down 97.3% from a year before. Europe was its largest region in fiscal year 2025, with 88% of revenue. Its market capitalization was $39.28 million.
Figures from company filings and market data; latest fiscal year ended December 31, 2024.
, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
FibroGen reported $29.62 million in revenue for fiscal year 2024, down 36.7% from $46.80 million in fiscal year 2023. In Q2 2025 revenue was $1.35 million.
Europe: 88% of revenue by region in fiscal year 2025, followed by Japan (12%).
$39.28 million.
Listed companies of a similar size in the same industry (drug manufacturing contractors) include Ortin Global Limited (ORTINGLOBE.NS), Euroapi S.a. (EAPI.PA), Nanoform Finland Oyj (NANOFH.HE), Pharmala Biotech Holdings Inc. (MDMA.CN).